AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05538910
Drug: Nicotine Patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug: 7.5 mg Nicotine Patch which will be administered in a double blind, randomized manner
Trial: NCT05773274
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05773274
Drug: Lutetium Lu 177 Dotatate
RxNorm normalized name: Lutetium Lu 177 dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05098574
Drug: Yaz
RxNorm normalized name: Yaz
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous treatment with 3mg drospirenone/ 0.02mg ethinyl estradiol for 12 weeks
Trial: NCT04433741
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin administered intravenously
Trial: NCT05137288
Drug: Ondansetron , atropine and bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% ) with morphine 250mic and atropine sulphate 100 micwith total volume = 2.5 ml .~Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% with 0.5 ml normal saline with morphine 250 mic ) with total volume = 2.5 ml with giving 4 mg IV ondansetron before anesthesia ( patients with body weight more than 80 Kg may need additional 4 mg IV ) .
Trial: NCT05033587
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib a multi-target receptor tyrosine kinase inhibitor.
Trial: NCT05033587
Drug: AK105
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AK105 is a humanized monoclonal antibody that specifically binds to PD-1.
Trial: NCT05055518
Drug: APL-102 Capsules
RxNorm normalized name: APL-502
DrugBank: APL-502 (DB17473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation: A total of seven dose levels (1mg, 2mg, 3mg, 5mg, 7mg, 9mg and 11mg) are planned.~Dose extension: After RP2D determined, the RP2D dose level will be extended to enroll 6-10 subjects to further evaluated the safety and antitumor activity of APL-102.
Trial: NCT05193201
Drug: recombinant human thrombopoietin injection
RxNorm normalized name: antihemophilic factor, human recombinant Injection [Recombinate]
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant human thrombopoietin: 15000 U subcutaneous injection once a day for 7 days
Trial: NCT00080080
Drug: talabostat (PT-100) tablets
RxNorm normalized name: Talabostat
DrugBank: Talabostat (DB06182)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00080080
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05750056
Drug: lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received an intravenous bolus injection of lidocaine 1.5 mg/kg over 10 min before induction of anesthesia, followed by a continuous infusion of 2 mg/kg/h until the end of the procedure.
Trial: NCT05750056
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An i.v. bolus injection of propofol 1 mg/kg was given to all patients. Propofol was then titrated if necessary to produce unconsciousness during the introduction of the endoscope. Afterward, the anesthesiologist determined the dose of propofol and titrated to effect.
Trial: NCT05898672
Drug: Nirmatrelvir/ritonavir
RxNorm normalized name: NIRMATRELVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Twice daily oral doses of nirmatrelvir/ritonavir tablets
Trial: NCT05129280
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
Trial: NCT06313502
Drug: 100gm HDAA
RxNorm normalized name: triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 100gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 180 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded.
Trial: NCT05137171
Drug: AK105 and anlotinib
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK105(penpulimab): 200mg, every 3 weeks, 21 days as a treatment cycle;Anlotinib: 12mg, 2 weeks on/1 week off, 21 days as a treatment cycle;Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, non-adherence to treatment or trial procedures.
Trial: NCT05295121
Drug: XC221 100 mg tablets
RxNorm normalized name: XC221
DrugBank: XC221 (DB16503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XC221, 3 discrete doses separated by 7-day wash-out periods
Trial: NCT05818956
Drug: TAK-227
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-227 capsules.
Trial: NCT03706573
Drug: alpelisib
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg and 200 mg film coated tablets administered orally once daily. Starting dose is 350 mg daily. Starting dose as a combination agent with endocrine partner is 300mg daily.
Trial: NCT06121609
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Exploring ED90 induced by remimazolam anesthesia in children of different age groups undergoing painless bidirectional endoscopy
Trial: NCT05487040
Drug: PF-07321332 (nirmatrelvir)/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients with Covid-19 infection and severe renal impairment. Capsule and tablet once a day by mouth.
Trial: NCT05866029
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Active Comparator: 60mg of Denosumab treatment by subcutaneous injection
Trial: NCT05866029
Drug: Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide was sequentially treated with Denosumab
Trial: NCT04964986
Drug: Apraglutide
RxNorm normalized name: Apraglutide
DrugBank: Apraglutide (DB18084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
Trial: NCT05735184
Drug: Ziftomenib
RxNorm normalized name: Ziftomenib
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Administration
Trial: NCT05735184
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Administration
Trial: NCT05735184
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous or Intravenous Administration
Trial: NCT05735184
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Administration
Trial: NCT05735184
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Administration
Trial: NCT06416358
Drug: ALMB-0168
RxNorm normalized name: ALMB-0168
DrugBank: ALMB-0168 (DB16926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
Trial: NCT06067100
Drug: Indacaterol and Mometasonefluroate (low dose)
RxNorm normalized name: indacaterol and mometasone
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are administered 125 µg indacaterol + mometasonefluroate
Trial: NCT06067100
Drug: Indacaterol and Mometasonefluroate (high dose)
RxNorm normalized name: indacaterol and mometasone
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are administered 500 µg indacaterol + mometasonefluroate
Trial: NCT06017609
Drug: JTT-861 Capsules
RxNorm normalized name: JTT-251
DrugBank: JTT-251 (DB18174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug capsules containing JTT-861
Trial: NCT06650748
Drug: Dalpiciclib
RxNorm normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpiciclib, oral administration, 125g each time, once daily, days 1-21, with a 28-day cycle (3 weeks on/1 week off). Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.
Trial: NCT06650748
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg, oral, once daily (continuously), with a 28-day cycle. Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage
Trial: NCT06657391
Drug: recombinant humanized anti-CD25 monoclonal antibody
RxNorm normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The intervention group received 4 doses of recombinant humanized anti-CD25 monoclonal antibody on days +7, +14, +28, and +42 after transplantation, with a recommended dose of 1 mg/kg.
Trial: NCT06658990
Drug: control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil is used after surgery
Trial: NCT06660524
Drug: Sevelamer
RxNorm normalized name: Sevelamer
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guidelines for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
Trial: NCT06660524
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guideline for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
Trial: NCT06658054
Drug: Control (Standard treatment)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will receive standard ESPB with bupivacaine and normal saline
Trial: NCT06658834
Drug: Dexamethasone Combined with romiplostim N01
RxNorm normalized name: Romiplostim
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dexamethasone (HD-DXM) at a dose of 40mg/d for 4 days constitutes one cycle. If there is no response on the 10th day, repeat it once. The administration can be either oral or intravenous. Meanwhile, romiplostim N01 is administered with an initial dose of 3µg/kg by subcutaneous injection once a week for up to 6 months.
Trial: NCT06658834
Drug: Dexamethasone monotherapy
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (HD-DXM) 40mg/d × 4 days, one cycle. If there is no response on the 10th day, repeat once, administered either orally or intravenously.
Trial: NCT06662175
Drug: Hyperbaric bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A (Unexposed) will received 2 ml of intrathecal bupivacaine
Trial: NCT06662175
Drug: hyperbaric bupivacaine and dexmedetomidine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group B (Exposed) will receive a combination of bupivacaine and Dexmedetomidine infusion
Trial: NCT06611345
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab 1500 mg will be administrated via Intravenous (IV) infusion Once Every 3 weeks (Q3W) on day 1 of each cycle for up to 8 cycles. And then 1500 mg Once Every 4 weeks (Q4W) on day 1 of each cycle until confirmed progressive disease (PD).
Trial: NCT06611345
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.
Trial: NCT06611345
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 25 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.
Trial: NCT04726592
Drug: Clorazepate Dipotassium
RxNorm normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorazepate Dipotassium : 20 mg intravenous injection
Trial: NCT04726592
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg IV
Trial: NCT06659471
Drug: 0.76% Sodium Monofluorophosphate Dentifrice
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Trial: NCT06659471
Drug: 0.454% Stannous Fluoride Dentifrice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Trial: NCT06660511
Drug: Disitamab Vedotin in Combination With Anlotinib Hydrochloride
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Anlotinib (DB11885)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dose of Disitamab Vedotin(RC48) is 2.0 mg/kg iv q2w d1; The dose of Anlotinib Hydrochloride Capsules is 10mg po qd (recommended to be taken before meals and at the same time every day), taken orally continuously for 2 weeks and stopped for 1 week, with a treatment cycle of 21 days.~Main research endpoint: Objective response rate (ORR)~Secondary study endpoint:~1. Progression free survival (PFS)~2. Overall survival (OS)~3. Disease Control Rate (DCR)~4. Objective Duration of Response (DoR)
Trial: NCT06660134
Drug: Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
RxNorm normalized name: Glucagon-like peptide II (2-glycine) (human)
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In addition to the routine use of Antiarrhythmic Drugs (AADs) and anticoagulants, the strict weight reduction intervention group also uses GLP-1 receptor agonists for glycemic control and weight loss according to guidelines. This group receives a structured weight loss program, regular nutritional advice in accordance with current guidelines, and physical training assistance over a 12-month period. The intervention plan aims for a total weight loss of 10 kilograms while using GLP-1 receptor agonists.
Trial: NCT06239220
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Epidermal growth factor receptor, via intravenous (into the vein) infusion per institutional standard of care.
Trial: NCT05858853
Drug: Human serum albumin
RxNorm normalized name: Human serum albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control drug (human blood albumin injection) 10 g/ day for 14 days
Trial: NCT05858853
Drug: Human serum albumin
RxNorm normalized name: Human serum albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control drug (human blood albumin injection) 20 g/ day for 7 days
Trial: NCT05898308
Drug: RiTUXimab Injection
RxNorm normalized name: rituximab Injection
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients assigned to the personalized maintenance treatment will be treated by additional RITUXIMAB injection depending on anti-Dsg Abs levels.
Trial: NCT02864888
Drug: Atengenal
RxNorm normalized name: ATENGENAL
DrugBank: Antineoplaston A10 (DB11702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
Trial: NCT02864888
Drug: Astugenal
RxNorm normalized name: ASTUGENAL COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
Trial: NCT05538312
Drug: vepdegestrant
RxNorm normalized name: Vepdegestrant
DrugBank: Vepdegestrant (DB19006)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of vepdegestrant by mouth in Period 1 and Period 2, with a washout period of at least 10 days between doses of vepdegestrant
Trial: NCT05538312
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive itraconazole by mouth once a day for 11 days in Period 2.
Trial: NCT06040918
Drug: N-803
RxNorm normalized name: N-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
DrugBank: Inbakicept (DB16479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fixed dose of 1 mg by subcutaneous (SC) injection
Trial: NCT06481371
Drug: Rabeprazole sodium enteric-coated tablets
RxNorm normalized name: rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For epigastric pain syndrome
Trial: NCT06481371
Drug: mosapride citrate
RxNorm normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial discomfort syndrome
Trial: NCT06447623
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib is a kind of TKI inhibitor.
Trial: NCT06447623
Drug: CDK4/6 Inhibitor
RxNorm normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.
Trial: NCT06447623
Drug: Aromatase inhibitor and Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
Trial: NCT05058612
Drug: Midodrine
RxNorm normalized name: Midodrine
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg PO/NG q8h
Trial: NCT05354466
Drug: Sugammadex injection
RxNorm normalized name: sugammadex Injection
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sugammadex as reversal agent
Trial: NCT05354466
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: neostigmine as a reversal agent
Trial: NCT00804752
Drug: Adding vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adding 1000IU/Vitamin D daily
Trial: NCT00804752
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of 1000IU/day Vitamin D
Trial: NCT04554966
Drug: ABBV-382
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT04554966
Drug: ABBV-382
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) injection
Trial: NCT05979220
Drug: Dalpiciclib combined with Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A multicenter, single arm, prospective Phase II clinical study
Trial: NCT00995397
Drug: Dexchlorpheniramine 1% lotion
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small amount applied over the lesion twice a day for 7 days.
Trial: NCT00995397
Drug: Dexchlorpheniramine 1% cream
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small amount applied over the lesion twice a day for 7 days.
Trial: NCT04771923
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical instillation of tranexamic acid up to 3x. If bleeding is not controlled patients crossover to adrenaline.
Trial: NCT04771923
Drug: Adrenaline
RxNorm normalized name: Adrenaline
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical instillation of adrenaline up to 3x. If bleeding is not controlled patients crossover to tranexamic acid.